Abbott Laboratories $ABT Shares Bought by Mill Creek Capital Advisors LLC

Key Points

• Mill Creek Capital Advisors LLC boosted its Abbott Laboratories stake by 258.1% in the fourth quarter, ending with 16,477 shares valued at about $2.06 million. Other institutional investors also increased or adjusted holdings, and institutions own 75.18% of the stock.
• Abbott continues to reward shareholders, declaring its 410th consecutive quarterly dividend and setting the payout at 63 cents per share. The dividend will be paid on August 17 and implies an annualized yield of about 2.9%.
• Analysts remain mostly positive but have become more cautious on price targets: several firms cut targets, including Bank of America reducing its target to $102. Despite that, Abbott beat quarterly EPS and revenue estimates, and the consensus rating remains Moderate Buy.

Mill Creek Capital Advisors LLC grew its position in shares of Abbott Laboratories (NYSE:ABT - Free Report) by 258.1% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 16,477 shares of the healthcare product maker's stock after acquiring an additional 11,876 shares during the quarter. Mill Creek Capital Advisors LLC's holdings in Abbott Laboratories were worth $2,064,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Minot DeBlois Advisors LLC lifted its holdings in Abbott Laboratories by 1.7% in the fourth quarter. Minot DeBlois Advisors LLC now owns 11,951 shares of the healthcare product maker's stock worth $1,497,000 after purchasing an additional 196 shares during the period. Focus Partners Wealth lifted its holdings in Abbott Laboratories by 197.0% in the fourth quarter. Focus Partners Wealth now owns 1,576,873 shares of the healthcare product maker's stock worth $197,567,000 after purchasing an additional 1,045,870 shares during the period. Graybill Wealth Management LTD. lifted its holdings in Abbott Laboratories by 2.3% in the fourth quarter. Graybill Wealth Management LTD. now owns 55,231 shares of the healthcare product maker's stock worth $6,920,000 after purchasing an additional 1,256 shares during the period. Healthcare of Ontario Pension Plan Trust Fund lifted its holdings in Abbott Laboratories by 40.3% in the fourth quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 875,340 shares of the healthcare product maker's stock worth $109,671,000 after purchasing an additional 251,441 shares during the period. Finally, Cornerstone Financial Management LLC acquired a new stake in Abbott Laboratories in the fourth quarter worth about $25,000. Institutional investors and hedge funds own 75.18% of the company's stock.

Key Abbott Laboratories News

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Abbott declared its 410th consecutive quarterly dividend, underscoring its long track record of returning cash to shareholders. The board approved a 63-cent per share quarterly dividend. Abbott declares 410th consecutive quarterly dividend
• Positive Sentiment: Erste Group Bank nudged its FY2026 EPS estimate higher for Abbott, aligning with the current consensus of $5.48 per share, which suggests analysts still see stable earnings power.
• Positive Sentiment: Abbott also continues to highlight growth opportunities in diabetes care and medtech, including an expanded MiniMed collaboration and recent CE Mark approval for Libre Duo, supporting the company’s innovation story.
• Neutral Sentiment: Research coverage remains mixed, with one Seeking Alpha piece calling Abbott “structurally undervalued,” but this is opinion-based and not a direct catalyst. Abbott Laboratories Remains Structurally Undervalued
• Neutral Sentiment: Erste Group also trimmed its FY2027 EPS estimate slightly to $6.04 from $6.05, a very small revision that should have limited impact on sentiment.
• Neutral Sentiment: Star51 Capital’s first close of its medtech fund included Abbott as a lead backer, reinforcing Abbott’s strategic interest in healthcare innovation, though the direct stock impact is likely modest.
• Negative Sentiment: BofA cut its price target on Abbott from $120 to $102, signaling less upside than before and likely adding to investor caution. BofA adjusts price target on Abbott Laboratories to 102 from 120
• Negative Sentiment: Recent trading has shown Abbott slipping more than the broader market, reflecting ongoing weakness in the shares and investor concern over valuation versus slower near-term momentum. Abbott (ABT) Dips More Than Broader Market
• Negative Sentiment: Portfolio filings showing Elfun Trusts exited Abbott may also add a small amount of selling pressure, though this is not a major fundamental development. Elfun Trusts Exits Abbott Laboratories

Analyst Ratings Changes

A number of equities research analysts have weighed in on ABT shares. The Goldman Sachs Group cut their price target on shares of Abbott Laboratories from $121.00 to $113.00 and set a "buy" rating for the company in a report on Wednesday, May 27th. Sanford C. Bernstein dropped their target price on Abbott Laboratories from $125.00 to $110.00 and set an "outperform" rating on the stock in a report on Friday, April 17th. Piper Sandler dropped their target price on Abbott Laboratories from $135.00 to $115.00 and set an "overweight" rating on the stock in a report on Friday, April 17th. Argus dropped their target price on Abbott Laboratories from $140.00 to $125.00 and set a "buy" rating on the stock in a report on Tuesday, April 21st. Finally, Bank of America dropped their target price on Abbott Laboratories from $150.00 to $120.00 and set a "buy" rating on the stock in a report on Friday, April 17th. Two analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and five have issued a Hold rating to the company's stock. Based on data from MarketBeat.com, Abbott Laboratories presently has an average rating of "Moderate Buy" and a consensus price target of $118.38.

Abbott Laboratories Trading Down 0.3%

NYSE:ABT opened at $87.89 on Monday. The company has a market capitalization of $153.08 billion, a P/E ratio of 24.62, a P/E/G ratio of 1.47 and a beta of 0.63. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.01 and a current ratio of 1.39. The stock's 50 day moving average price is $91.46 and its 200 day moving average price is $107.84. Abbott Laboratories has a 52 week low of $81.97 and a 52 week high of $139.06.

Abbott Laboratories (NYSE:ABT - Get Free Report) last announced its earnings results on Thursday, April 16th. The healthcare product maker reported $1.15 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.14 by $0.01. The firm had revenue of $11.16 billion during the quarter, compared to analysts' expectations of $10.99 billion. Abbott Laboratories had a return on equity of 17.62% and a net margin of 13.90%.The company's revenue was up 7.8% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.09 earnings per share. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. On average, research analysts forecast that Abbott Laboratories will post 5.48 EPS for the current fiscal year.

Abbott Laboratories Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, August 17th. Investors of record on Wednesday, July 15th will be given a $0.63 dividend. This represents a $2.52 annualized dividend and a yield of 2.9%. The ex-dividend date of this dividend is Wednesday, July 15th. Abbott Laboratories's dividend payout ratio (DPR) is 70.59%.

Insider Buying and Selling at Abbott Laboratories

In other Abbott Laboratories news, CFO Philip P. Boudreau purchased 2,200 shares of the company's stock in a transaction that occurred on Thursday, April 23rd. The stock was purchased at an average price of $91.50 per share, with a total value of $201,300.00. Following the completion of the transaction, the chief financial officer directly owned 2,200 shares of the company's stock, valued at approximately $201,300. This trade represents a ∞ increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Daniel J. Starks acquired 10,000 shares of the business's stock in a transaction on Monday, April 27th. The shares were bought at an average cost of $92.65 per share, with a total value of $926,500.00. Following the completion of the acquisition, the director owned 6,751,103 shares of the company's stock, valued at approximately $625,489,692.95. This trade represents a 0.15% increase in their position. The SEC filing for this purchase provides additional information. 0.46% of the stock is owned by company insiders.

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.

Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.